Atherosclerotic Cardiovascular Disease, Diabetes, Familial Hypercholesterolemia
Conditions
Brief summary
This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480 participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (for example, diabetes and familial hypercholesterolemia) and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of ALN-PCSSC injection(s).
Detailed description
Participants will be screened and 480 eligible participants will be randomized: 60 participants per each of six ALN-PCSSC dose groups plus 120 participants total across the placebo groups (20 participants each to match each of the six drug dose groups). Treatment allocation will be stratified by country and by current use of statins or other lipid-modifying therapies. Each participant will receive either one or two injections on Day 1 or a single injection on Day 1 and on Day 90 of blinded ALN-PCSSC or placebo. Formation of anti-drug antibodies (ADA) will be assessed on Day 1 (prior to and 4 hours after the injection) and on Days 30, 60, 90, 120, 150, 180 (Days 150 and 180 only in participants who receive a second dose of study drug), and 210 or until any ADA response becomes negative within the study duration. The independent Data Monitoring Committee (DMC) will review safety data beginning after the first 40 participants receive the first injection of ALN-PCSSC or placebo and complete the Day 14 follow-up visit. Thereafter, the DMC will review safety data every 2 months until the end of the trial. A recommendation may be taken to stop or amend the study at any of these reviews. On Day 1, all eligible participants will be randomized and receive the first subcutaneous (SC) administration of ALN-PCSSC or placebo. After the first study drug administration, the participant will be observed in the clinic for at least 4 hours post injection before being discharged. Participants will return at Day 14 and then at monthly intervals for 6 months. Participants randomized to receive a second dose of study drug will receive the second injection of ALN-PCSSC or placebo at the Day 90 visit. Efficacy assessments will include the measurement of the effects of ALN-PCSSC on levels of LDL-C lipids and lipoproteins including total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, very low-density lipoprotein (VLDL), apolipoprotein A1 (Apo-AI), apolipoprotein B (Apo-B), lipoprotein (a) \[Lp(a)\], C-reactive protein (CRP), and proprotein convertase subtilisin/kexin type 9 (PCSK9). End of study (EOS) evaluations will be conducted at the EOS visit (Day 210). The expected duration of the participants' involvement in the study will be approximately 374 days, which includes screening, study drug administration, the course of single or multiple injections, and the follow-up period to Day 360. Participants completing the study to Day 210 will be given the opportunity to enroll in a separate long-term extension study. Any participants in whom LDL-C levels have not returned to \>80% of baseline values will continue to be followed as part of this study until either this level has been reached or until a maximum of Day 360, at which point they will be given the opportunity to enroll in the long-term extension study. At each visit, LDL-C levels, adverse events, serious adverse events, concomitant medications, and safety laboratory assessments will be collected. Objectives: Primary: To evaluate the effect of ALN-PCSSC treatment on LDL-C levels at Day 180. Secondary: To evaluate the effect of ALN-PCSSC on the following: * LDL-C at Day 90 * LDL-C levels at other time points * PCSK9 levels over time * Other lipids, lipoproteins, apolipoproteins * Proportion of participants achieving pre-specified global lipid guidelines * Individual responsiveness to different doses * Duration of lipid-lowering effect of different doses * Safety and tolerability profile of ALN-PCSSC Exploratory: To collect/evaluate the effect of ALN-PCSSC on the following: * Cardiovascular (CV) events such as CV death, non-fatal myocardial infarction, resuscitated cardiac arrest and non-fatal stroke (ischemic and hemorrhagic) * Evaluation of ADA for the investigational product
Interventions
DRUGALN-PCSSC
ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections
DRUGNormal Saline
Saline (sterile, normal, 0.9%) solution given as SC injections
Sponsors
The Medicines Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female participants ≥18 years of age. 2. History of ASCVD or ASCVD-risk equivalents (symptomatic atherosclerosis, Type 2 diabetes, familial hypercholesterolemia, including participants whose 10-year risk of a CV event assessed by Framingham Risk Score (Framingham Risk Score \>20%) or equivalent has a target LDL-C of \<100 mg/deciliter \[dL\]). 3. Serum LDL-C ≥1.8 millimole (mmol)/liter (L) (≥70 mg/dL) for ASCVD participants or ≥2.6 mmol/L (≥100 mg/dL) for ASCVD-risk equivalent participants at screening. 4. Fasting triglyceride \<4.52 mmol/L (\<400 mg/dL) at screening. 5. Calculated glomerular filtration rate 30 mL/min or higher by estimated glomerular filtration rate (eGFR) using standardized local clinical methodology. 6. Participants on statins should be receiving a maximally tolerated dose (investigator's discretion). 7. Participants on lipid-lower therapies (such as statin and/or ezetimibe) should be on a stable dose for ≥30 days before screening with no planned medication or dose change during study participation. 8. Willing and able to give informed consent before initiation of any study-related procedures and willing to comply with all required study procedures.
Exclusion criteria
1. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the participant at significant risk (according to investigator's \[or delegate\] judgment) if he/she participates in the clinical study. 2. An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate), might interfere with interpretation of the clinical study results. 3. New York Heart Association (NYHA) class II, III, or IV heart failure or last known left ventricular ejection fraction \<30%. 4. Cardiac arrhythmia within 3 months prior to randomization that is not controlled by medication or via ablation. 5. Any history of hemorrhagic stroke. 6. Major adverse cardiac event within 6 months prior to randomization. 7. Uncontrolled severe hypertension: systolic blood pressure \>180 millimeters of mercury (mmHg) or diastolic blood pressure \>110 mmHg prior to randomization despite anti-hypertensive therapy. 8. Poorly controlled Type 2 diabetes, such as, glycated hemoglobin A1c (HbA1c)\>10.0% prior to randomization. 9. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation \>2x the upper limit of normal (ULN), or total bilirubin elevation \>1.5x ULN at screening confirmed by a repeat measurement at least 1 week apart. 10. Serious comorbid disease in which the life expectancy of the participant is shorter than the duration of the trial (for example, acute systemic infection, cancer, or other serious illnesses). This includes all cancers with the exception of treated basal-cell carcinoma occurring \>5 years before screening. 11. Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least two methods of contraception (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device or tubal litigation) for the entire duration of the study. Women who are \>2 years postmenopausal defined as ≥1 year since last menstrual period and if less than 55 years old with a negative pregnancy test within 24 hours of randomization or surgically sterile are exempt from this exclusion. 12. Males who are unwilling to use an acceptable method of birth control during the entire study period (such as, condom with spermicide). 13. Known history of alcohol and/or drug abuse within the last 5 years. 14. Treatment with other investigational medicinal products or devices within 30 days or five half˗lives, whichever is longer. 15. Use of other investigational medicinal products or devices during the course of the study. 16. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to the following: * Inappropriate for this study, including participants who are unable to communicate or to cooperate with the investigator. * Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including participants whose cooperation is doubtful due to drug abuse or alcohol dependency). * Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (for example, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study). * Have any medical or surgical condition, which in the opinion of the investigator would put the participants at increased risk from participating in the study. * Involved with, or a relative of, someone directly involved in the conduct of the study. * Any known cognitive impairment (for example, Alzheimer's disease) 17. Previous or current treatment (within 90 days of screening) with monoclonal antibodies directed at PCSK9.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage Change in LDL-C From Baseline to Day 180 | Baseline to 180 days | Percent Change in LDL-C (beta-quantification) from Baseline to Day 180 in MITT Population |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Baseline, Day 60, Day 120, and Day 210 | This outcome measure evaluated the effects of both single- and double-dose inclisiran on LDL-C levels in the mITT population from baseline to Day 60, Day 120, and Day 210. |
| Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Baseline, Day 180, Day 210 | This outcome measure evaluated the number of participants (single and double dose) in the mITT population with an LDL-C greater than 80% of the baseline value at Day 180 and Day 210. |
| Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 90, Day 180 | This outcome measure evaluated the individual responsiveness of participants to inclisiran (single and double dose) in the mITT population as defined by an LDL-C level of \<25 mg/deciliter \[dL\] at Day 90 and Day 180. |
| Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180 | Baseline, Day 180 | This outcome measure evaluated the number of participants (single and double dose) in the mITT population with an LDL-C reduction greater than 50% of the baseline value at Day 180. |
| Percentage Change in LDL-C From Baseline to Day 90 | Baseline to 90 days | Percent Change in LDL-C (beta-quantification) from Baseline to Day 90 in MITT Population |
| Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Baseline, Day 180 | This outcome measure evaluated the percent change from baseline to Day 180 in cholesterol (total, high-density lipoprotein \[HDL\], non-HDL) and apolipoproteins (B, A1) in participants (single and double dose) in the mITT population. |
| Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | Baseline, Day 180 | This outcome measure evaluated the proportion of participants (single and double dose) in the mITT population who attained a global lipid modification target by baseline cardiovascular risk group, looking specifically at LDL-C levels (mg/dL) in the category of cardiovascular disease (CVD). CVD was defined as a participant who had at least 1 of the following: prior myocardial infarction, prior percutaneous coronary intervention, prior coronary artery bypass graft, prior stroke, prior transient ischemic attack, peripheral artery disease. |
| Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Baseline, Day 180 | This outcome measure evaluated the percent change from baseline to Day 180 in triglycerides, very-low-density lipoprotein (VLDL) cholesterol, lipoprotein(a), and high sensitivity C-reactive protein (hsCRP) in participants (single and double dose) in the mITT population. |
| Percentage Change in PCSK9 Levels From Baseline at Day 180 | Baseline, Day 180 | This outcome measure evaluated the percent change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to Day 180 in participants (single and double dose) in the mITT population. |
Countries
Canada, Germany, Netherlands, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo (Single-dose) Saline subcutaneous administration once at Day 1 | 65 |
| Inclisiran 200 mg (Single-dose) 200 mg subcutaneous administration once at Day 1 | 60 |
| Inclisiran 300 mg (Single-dose) 300 mg subcutaneous administration once at Day 1 | 62 |
| Inclisiran 500 mg (Single-dose) 500 mg subcutaneous administration once at Day 1 | 66 |
| Placebo (Double-dose) Saline subcutaneous administration at Day 1 and Day 90 | 62 |
| Inclisiran 100 mg (Double-dose) 100 mg subcutaneous administration at Day 1 and Day 90 | 62 |
| Inclisiran 200 mg (Double-dose) 200 mg subcutaneous administration at Day 1 and Day 90 | 63 |
| Inclisiran 300 mg (Double-dose) 300 mg subcutaneous administration at Day 1 and Day 90 | 61 |
| Total | 501 |
Baseline characteristics
| Characteristic | Placebo (Single-dose) | Inclisiran 200 mg (Single-dose) | Inclisiran 300 mg (Single-dose) | Inclisiran 500 mg (Single-dose) | Placebo (Double-dose) | Inclisiran 100 mg (Double-dose) | Inclisiran 200 mg (Double-dose) | Inclisiran 300 mg (Double-dose) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 25 Participants | 30 Participants | 35 Participants | 34 Participants | 30 Participants | 38 Participants | 26 Participants | 30 Participants | 248 Participants |
| Age, Categorical Between 18 and 65 years | 40 Participants | 30 Participants | 27 Participants | 32 Participants | 32 Participants | 24 Participants | 37 Participants | 31 Participants | 253 Participants |
| Age, Continuous | 62.0 years STANDARD_DEVIATION 11.4 | 63.9 years STANDARD_DEVIATION 10.8 | 64.1 years STANDARD_DEVIATION 12.8 | 62.1 years STANDARD_DEVIATION 12.4 | 62.8 years STANDARD_DEVIATION 10.3 | 65.2 years STANDARD_DEVIATION 9.4 | 62.3 years STANDARD_DEVIATION 10.8 | 64.1 years STANDARD_DEVIATION 9.4 | 63.6 years STANDARD_DEVIATION 10 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 7 Participants | 4 Participants | 3 Participants | 1 Participants | 2 Participants | 2 Participants | 6 Participants | 4 Participants | 29 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 58 Participants | 56 Participants | 59 Participants | 65 Participants | 60 Participants | 60 Participants | 57 Participants | 57 Participants | 472 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 6 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 2 Participants | 2 Participants | 2 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 9 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 4 Participants | 2 Participants | 0 Participants | 3 Participants | 2 Participants | 2 Participants | 1 Participants | 18 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) White | 59 Participants | 53 Participants | 56 Participants | 63 Participants | 58 Participants | 57 Participants | 61 Participants | 58 Participants | 465 Participants |
| Region of Enrollment Canada | 8 Participants | 8 Participants | 7 Participants | 12 Participants | 10 Participants | 10 Participants | 7 Participants | 9 Participants | 71 Participants |
| Region of Enrollment Germany | 12 Participants | 10 Participants | 13 Participants | 10 Participants | 14 Participants | 13 Participants | 10 Participants | 9 Participants | 91 Participants |
| Region of Enrollment Netherlands | 22 Participants | 21 Participants | 21 Participants | 21 Participants | 20 Participants | 20 Participants | 23 Participants | 21 Participants | 169 Participants |
| Region of Enrollment United Kingdom | 11 Participants | 11 Participants | 11 Participants | 11 Participants | 10 Participants | 9 Participants | 11 Participants | 12 Participants | 86 Participants |
| Region of Enrollment United States | 12 Participants | 10 Participants | 10 Participants | 12 Participants | 8 Participants | 10 Participants | 12 Participants | 10 Participants | 84 Participants |
| Sex: Female, Male Female | 23 Participants | 21 Participants | 20 Participants | 19 Participants | 29 Participants | 23 Participants | 24 Participants | 16 Participants | 175 Participants |
| Sex: Female, Male Male | 42 Participants | 39 Participants | 42 Participants | 47 Participants | 33 Participants | 39 Participants | 39 Participants | 45 Participants | 326 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 65 | 0 / 60 | 0 / 61 | 1 / 65 | 0 / 62 | 0 / 61 | 1 / 62 | 0 / 61 |
| other Total, other adverse events | 50 / 65 | 49 / 60 | 49 / 61 | 54 / 65 | 51 / 62 | 47 / 61 | 49 / 62 | 51 / 61 |
| serious Total, serious adverse events | 3 / 65 | 11 / 60 | 11 / 61 | 8 / 65 | 7 / 62 | 13 / 61 | 8 / 62 | 9 / 61 |
Outcome results
Primary
Percentage Change in LDL-C From Baseline to Day 180
Percent Change in LDL-C (beta-quantification) from Baseline to Day 180 in MITT Population
Time frame: Baseline to 180 days
Population: Modified intent-to-treat (MITT) population
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (Single Dose) | Percentage Change in LDL-C From Baseline to Day 180 | 2.1 Percent change |
| 200 mg (Single Dose) | Percentage Change in LDL-C From Baseline to Day 180 | -27.9 Percent change |
| 300 mg (Single Dose) | Percentage Change in LDL-C From Baseline to Day 180 | -38.4 Percent change |
| 500 mg (Single Dose) | Percentage Change in LDL-C From Baseline to Day 180 | -41.9 Percent change |
| Placebo (Double Dose) | Percentage Change in LDL-C From Baseline to Day 180 | 1.8 Percent change |
| 100 mg (Double Dose) | Percentage Change in LDL-C From Baseline to Day 180 | -35.5 Percent change |
| 200 mg (Double Dose) | Percentage Change in LDL-C From Baseline to Day 180 | -44.9 Percent change |
| 300 mg (Double Dose) | Percentage Change in LDL-C From Baseline to Day 180 | -52.6 Percent change |
p-value: <0.0001t-test, 1 sided
p-value: <0.0001t-test, 1 sided
p-value: <0.0001t-test, 1 sided
p-value: <0.0001t-test, 1 sided
p-value: <0.0001t-test, 1 sided
p-value: <0.0001t-test, 1 sided
Secondary
Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk
This outcome measure evaluated the proportion of participants (single and double dose) in the mITT population who attained a global lipid modification target by baseline cardiovascular risk group, looking specifically at LDL-C levels (mg/dL) in the category of cardiovascular disease (CVD). CVD was defined as a participant who had at least 1 of the following: prior myocardial infarction, prior percutaneous coronary intervention, prior coronary artery bypass graft, prior stroke, prior transient ischemic attack, peripheral artery disease.
Time frame: Baseline, Day 180
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo (Single Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | CVD | 45 Participants |
| Placebo (Single Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | <70 mg/dL | 0 Participants |
| 200 mg (Single Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | CVD | 43 Participants |
| 200 mg (Single Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | <70 mg/dL | 16 Participants |
| 300 mg (Single Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | CVD | 46 Participants |
| 300 mg (Single Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | <70 mg/dL | 27 Participants |
| 500 mg (Single Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | CVD | 33 Participants |
| 500 mg (Single Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | <70 mg/dL | 18 Participants |
| Placebo (Double Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | CVD | 45 Participants |
| Placebo (Double Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | <70 mg/dL | 1 Participants |
| 100 mg (Double Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | CVD | 41 Participants |
| 100 mg (Double Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | <70 mg/dL | 24 Participants |
| 200 mg (Double Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | <70 mg/dL | 27 Participants |
| 200 mg (Double Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | CVD | 39 Participants |
| 300 mg (Double Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | CVD | 42 Participants |
| 300 mg (Double Dose) | Number of Participants Who Attained Global Lipid Modification Targets for Level of Atherosclerotic Cardiovascular Disease Risk | <70 mg/dL | 33 Participants |
Secondary
Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210
This outcome measure evaluated the number of participants (single and double dose) in the mITT population with an LDL-C greater than 80% of the baseline value at Day 180 and Day 210.
Time frame: Baseline, Day 180, Day 210
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo (Single Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 180 | 35 Participants |
| Placebo (Single Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 210 | 34 Participants |
| 200 mg (Single Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 180 | 6 Participants |
| 200 mg (Single Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 210 | 8 Participants |
| 300 mg (Single Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 180 | 5 Participants |
| 300 mg (Single Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 210 | 5 Participants |
| 500 mg (Single Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 180 | 0 Participants |
| 500 mg (Single Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 210 | 2 Participants |
| Placebo (Double Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 180 | 29 Participants |
| Placebo (Double Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 210 | 34 Participants |
| 100 mg (Double Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 180 | 2 Participants |
| 100 mg (Double Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 210 | 1 Participants |
| 200 mg (Double Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 210 | 1 Participants |
| 200 mg (Double Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 180 | 1 Participants |
| 300 mg (Double Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 180 | 0 Participants |
| 300 mg (Double Dose) | Number of Participants With an LDL-C Greater Than 80% of the Baseline Value at Day 180 and Day 210 | Day 210 | 1 Participants |
Secondary
Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180
This outcome measure evaluated the number of participants (single and double dose) in the mITT population with an LDL-C reduction greater than 50% of the baseline value at Day 180.
Time frame: Baseline, Day 180
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo (Single Dose) | Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180 | 0 Participants |
| 200 mg (Single Dose) | Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180 | 9 Participants |
| 300 mg (Single Dose) | Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180 | 19 Participants |
| 500 mg (Single Dose) | Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180 | 16 Participants |
| Placebo (Double Dose) | Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180 | 0 Participants |
| 100 mg (Double Dose) | Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180 | 14 Participants |
| 200 mg (Double Dose) | Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180 | 27 Participants |
| 300 mg (Double Dose) | Number of Participants With Greater Or Equal To 50% LDL-C Reduction From Baseline At Day 180 | 32 Participants |
Secondary
Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180
This outcome measure evaluated the individual responsiveness of participants to inclisiran (single and double dose) in the mITT population as defined by an LDL-C level of \<25 mg/deciliter \[dL\] at Day 90 and Day 180.
Time frame: Day 90, Day 180
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo (Single Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 90 | 0 Participants |
| Placebo (Single Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 180 | 0 Participants |
| 200 mg (Single Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 90 | 0 Participants |
| 200 mg (Single Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 180 | 0 Participants |
| 300 mg (Single Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 90 | 5 Participants |
| 300 mg (Single Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 180 | 1 Participants |
| 500 mg (Single Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 90 | 3 Participants |
| 500 mg (Single Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 180 | 2 Participants |
| Placebo (Double Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 90 | 0 Participants |
| Placebo (Double Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 180 | 0 Participants |
| 100 mg (Double Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 90 | 0 Participants |
| 100 mg (Double Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 180 | 1 Participants |
| 200 mg (Double Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 180 | 2 Participants |
| 200 mg (Double Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 90 | 1 Participants |
| 300 mg (Double Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 90 | 0 Participants |
| 300 mg (Double Dose) | Number of Participants With Individual Responsiveness as Measured By LDL-C Levels at Day 90 and Day 180 | Day 180 | 3 Participants |
Secondary
Percentage Change in LDL-C From Baseline to Day 90
Percent Change in LDL-C (beta-quantification) from Baseline to Day 90 in MITT Population
Time frame: Baseline to 90 days
Population: In this analysis, the single and double-dose 200mg arms were combined, as were the single and double-dose 300mg arms. The second dose for patients in double-dose arms was given on Day 90. Therefore, up to day 90, those patients in double-dose arms received the same treatment as patients in the single dose arms within the same dose amount.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Placebo (Single Dose) | Percentage Change in LDL-C From Baseline to Day 90 | -49 Percent change |
| 200 mg (Single Dose) | Percentage Change in LDL-C From Baseline to Day 90 | -34.2 Percent change |
| 300 mg (Single Dose) | Percentage Change in LDL-C From Baseline to Day 90 | -0.8 Percent change |
| 500 mg (Single Dose) | Percentage Change in LDL-C From Baseline to Day 90 | -41.8 Percent change |
| Placebo (Double Dose) | Percentage Change in LDL-C From Baseline to Day 90 | -45.7 Percent change |
Secondary
Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180
This outcome measure evaluated the percent change from baseline to Day 180 in cholesterol (total, high-density lipoprotein \[HDL\], non-HDL) and apolipoproteins (B, A1) in participants (single and double dose) in the mITT population.
Time frame: Baseline, Day 180
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | HDL Cholesterol | 3.8 percent change | Standard Deviation 15.6 |
| Placebo (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Non-HDL Cholesterol | 1.5 percent change | Standard Deviation 16.7 |
| Placebo (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Total Cholesterol | 1.8 percent change | Standard Deviation 12.1 |
| Placebo (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein A1 | 3.6 percent change | Standard Deviation 10.6 |
| Placebo (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein B | 1.7 percent change | Standard Deviation 14.7 |
| 200 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein A1 | 2.9 percent change | Standard Deviation 9.3 |
| 200 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Total Cholesterol | -17.6 percent change | Standard Deviation 19 |
| 200 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Non-HDL Cholesterol | -25.1 percent change | Standard Deviation 26.3 |
| 200 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | HDL Cholesterol | 4.4 percent change | Standard Deviation 14.8 |
| 200 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein B | -22.9 percent change | Standard Deviation 21 |
| 300 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Non-HDL Cholesterol | -35.2 percent change | Standard Deviation 20.2 |
| 300 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | HDL Cholesterol | 8.8 percent change | Standard Deviation 11.1 |
| 300 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Total Cholesterol | -23.7 percent change | Standard Deviation 15.7 |
| 300 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein B | -30.8 percent change | Standard Deviation 18 |
| 300 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein A1 | 3.8 percent change | Standard Deviation 8.9 |
| 500 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein B | -33.1 percent change | Standard Deviation 12.7 |
| 500 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | HDL Cholesterol | 6.9 percent change | Standard Deviation 14 |
| 500 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Total Cholesterol | -26.6 percent change | Standard Deviation 10.7 |
| 500 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein A1 | 4.1 percent change | Standard Deviation 10.9 |
| 500 mg (Single Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Non-HDL Cholesterol | -36.9 percent change | Standard Deviation 14 |
| Placebo (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Total Cholesterol | 0.7 percent change | Standard Deviation 12.3 |
| Placebo (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein B | 0.9 percent change | Standard Deviation 13 |
| Placebo (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | HDL Cholesterol | 0.5 percent change | Standard Deviation 12.5 |
| Placebo (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein A1 | 0.8 percent change | Standard Deviation 8.3 |
| Placebo (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Non-HDL Cholesterol | 1.3 percent change | Standard Deviation 16.9 |
| 100 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein B | -27.8 percent change | Standard Deviation 13.4 |
| 100 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | HDL Cholesterol | 7.6 percent change | Standard Deviation 12.2 |
| 100 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Total Cholesterol | -22.4 percent change | Standard Deviation 12.4 |
| 100 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Non-HDL Cholesterol | -31.7 percent change | Standard Deviation 15.1 |
| 100 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein A1 | 5.5 percent change | Standard Deviation 10.6 |
| 200 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Non-HDL Cholesterol | -38.9 percent change | Standard Deviation 16.8 |
| 200 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | HDL Cholesterol | 10.3 percent change | Standard Deviation 15.3 |
| 200 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Total Cholesterol | -26.8 percent change | Standard Deviation 13 |
| 200 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein B | -35 percent change | Standard Deviation 15.8 |
| 200 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein A1 | 8.6 percent change | Standard Deviation 11.5 |
| 300 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein B | -40.9 percent change | Standard Deviation 14.8 |
| 300 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Total Cholesterol | 33.2 percent change | Standard Deviation 11.3 |
| 300 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | HDL Cholesterol | 8.6 percent change | Standard Deviation 14.9 |
| 300 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Apolipoprotein A1 | 6.2 percent change | Standard Deviation 11.9 |
| 300 mg (Double Dose) | Percentage Change in Other Lipids and Apolipoproteins From Baseline to Day 180 | Non-HDL Cholesterol | -46 percent change | Standard Deviation 14.6 |
Secondary
Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180
This outcome measure evaluated the percent change from baseline to Day 180 in triglycerides, very-low-density lipoprotein (VLDL) cholesterol, lipoprotein(a), and high sensitivity C-reactive protein (hsCRP) in participants (single and double dose) in the mITT population.
Time frame: Baseline, Day 180
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Placebo (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Triglycerides | 6.4 percent change |
| Placebo (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | VLDL Cholesterol | 2.4 percent change |
| Placebo (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Lipoprotein(a) | 0.5 percent change |
| Placebo (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | hsCRP | -5.3 percent change |
| 200 mg (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | hsCRP | 7.1 percent change |
| 200 mg (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | VLDL Cholesterol | -11.6 percent change |
| 200 mg (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Triglycerides | 1.1 percent change |
| 200 mg (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Lipoprotein(a) | -14.3 percent change |
| 300 mg (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Triglycerides | -12.8 percent change |
| 300 mg (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | hsCRP | -16.2 percent change |
| 300 mg (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | VLDL Cholesterol | -23.8 percent change |
| 300 mg (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Lipoprotein(a) | -14.3 percent change |
| 500 mg (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Triglycerides | -12.2 percent change |
| 500 mg (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | VLDL Cholesterol | -14.6 percent change |
| 500 mg (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Lipoprotein(a) | -18.2 percent change |
| 500 mg (Single Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | hsCRP | -19.8 percent change |
| Placebo (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | hsCRP | -20 percent change |
| Placebo (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Lipoprotein(a) | 0 percent change |
| Placebo (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | VLDL Cholesterol | 2.7 percent change |
| Placebo (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Triglycerides | -3 percent change |
| 100 mg (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | hsCRP | -12.5 percent change |
| 100 mg (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Lipoprotein(a) | -14.9 percent change |
| 100 mg (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | VLDL Cholesterol | -16.4 percent change |
| 100 mg (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Triglycerides | -6.3 percent change |
| 200 mg (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | hsCRP | -16.3 percent change |
| 200 mg (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Triglycerides | 0.7 percent change |
| 200 mg (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Lipoprotein(a) | -17.3 percent change |
| 200 mg (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | VLDL Cholesterol | -21.2 percent change |
| 300 mg (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | VLDL Cholesterol | -16 percent change |
| 300 mg (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Lipoprotein(a) | -25.6 percent change |
| 300 mg (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | hsCRP | -16.7 percent change |
| 300 mg (Double Dose) | Percentage Change in Other Lipids and Inflammatory Markers From Baseline to Day 180 | Triglycerides | -14.2 percent change |
Secondary
Percentage Change in PCSK9 Levels From Baseline at Day 180
This outcome measure evaluated the percent change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to Day 180 in participants (single and double dose) in the mITT population.
Time frame: Baseline, Day 180
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo (Single Dose) | Percentage Change in PCSK9 Levels From Baseline at Day 180 | 2.2 percent change | Standard Deviation 23.4 |
| 200 mg (Single Dose) | Percentage Change in PCSK9 Levels From Baseline at Day 180 | -47.9 percent change | Standard Deviation 21 |
| 300 mg (Single Dose) | Percentage Change in PCSK9 Levels From Baseline at Day 180 | -56 percent change | Standard Deviation 19.2 |
| 500 mg (Single Dose) | Percentage Change in PCSK9 Levels From Baseline at Day 180 | -59.3 percent change | Standard Deviation 18 |
| Placebo (Double Dose) | Percentage Change in PCSK9 Levels From Baseline at Day 180 | -1.2 percent change | Standard Deviation 20.7 |
| 100 mg (Double Dose) | Percentage Change in PCSK9 Levels From Baseline at Day 180 | -53.2 percent change | Standard Deviation 20.9 |
| 200 mg (Double Dose) | Percentage Change in PCSK9 Levels From Baseline at Day 180 | -66.2 percent change | Standard Deviation 15.6 |
| 300 mg (Double Dose) | Percentage Change in PCSK9 Levels From Baseline at Day 180 | -69.1 percent change | Standard Deviation 12.1 |
Secondary
Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210
This outcome measure evaluated the effects of both single- and double-dose inclisiran on LDL-C levels in the mITT population from baseline to Day 60, Day 120, and Day 210.
Time frame: Baseline, Day 60, Day 120, and Day 210
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Placebo (Single Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 60 | -4.27 Percent change |
| Placebo (Single Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 210 | 1.45 Percent change |
| Placebo (Single Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 120 | -0.91 Percent change |
| 200 mg (Single Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 210 | -28.98 Percent change |
| 200 mg (Single Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 120 | -36.94 Percent change |
| 200 mg (Single Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 60 | -44.32 Percent change |
| 300 mg (Single Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 210 | -35.39 Percent change |
| 300 mg (Single Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 60 | -50.87 Percent change |
| 300 mg (Single Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 120 | -43.32 Percent change |
| 500 mg (Single Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 60 | -49.58 Percent change |
| 500 mg (Single Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 120 | -46.42 Percent change |
| 500 mg (Single Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 210 | -39.2 Percent change |
| Placebo (Double Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 120 | 0.17 Percent change |
| Placebo (Double Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 60 | -1.92 Percent change |
| Placebo (Double Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 210 | 0.58 Percent change |
| 100 mg (Double Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 120 | -41.37 Percent change |
| 100 mg (Double Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 60 | -35.73 Percent change |
| 100 mg (Double Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 210 | -31.67 Percent change |
| 200 mg (Double Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 120 | -49.54 Percent change |
| 200 mg (Double Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 60 | -44.28 Percent change |
| 200 mg (Double Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 210 | -42.59 Percent change |
| 300 mg (Double Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 60 | -50.99 Percent change |
| 300 mg (Double Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 120 | -54.73 Percent change |
| 300 mg (Double Dose) | Percent Change From Baseline In LDL-C Levels At Day 60, Day 120, and Day 210 | Day 210 | -50.54 Percent change |